Ranbaxy halts drug ingredient shipments from two plants as scrutiny mounts

Ranbaxy Laboratories, hit by a rash of sanctions by the U.S. regulator, has suspended shipments of pharmaceutical ingredients from two plants amid growing scrutiny of its manufacturing processes by other regulators.

http://in.reuters.com/article/2014/02/25/daiichi-sankyo-ranbaxy-fda-idINDEEA1O00520140225

YOU ARE BEING REDIRECTED TO THE ARTICLE
. . .
× CLOSE

PROCESSING